Pronto disponible para inscripción

This study will open for enrollment soon. Please contact the study team for more information and check back frequently.

GDFATHER-CTL002004 (Non-Small Cell Lung Cancer) - Clinical Trial

¿Cuál es el Propósito de este estudio?

We are doing this study to find the most effective, safe dose of an experimental drug called CTL-002 (the study drug) when it is given in combination with nivolumab and docetaxel for patients who have metastatic non-squamous non-small cell lung cancer (NSCLC).

¿Cuál es la Condición que se está estudiando?

Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

¿Quién puede participar en el Estudio?

Adults ages 18+ who:

Are diagnosed with stage IV non-squamous NSCLC
Do not have any known mutations (e.g. EGFR, ALK, among others) that can guide treatment with an available targeted agent
Have not have received more than one line of prior systemic treatment for advanced/metastatic NSCLC

For more information about who can join this study, contact the study team at annemarie.peters@duke.edu.

Grupo etario

Adultos

¿Qué Implica?

If you choose to join this study, you will get a random assignment (by chance) to 1 of 4 different study groups. The possible group assignments are as follows:

Group A: If you are in this group, you will get the study drug and nivolumab along with docetaxel.
Group B: If you are in this group, you will get the study drug and nivolumab along with docetaxel, but the study drug will be given at a lower dose than Group A.
Group C: If you are in this group, you will get the study drug and nivolumab without docetaxel. The dose of the study drug will be the same as the dose used in Group A.
Group D: If you are in this group, you will get docetaxel on its own.

You will get the drug(s) in your assigned group every 3 weeks for up to 2 years.

Detalles del Estudio

Título Completo

A Phase 2, Randomized, Blinded, Placebo-Controlled Trial Investigating the Efficacy and Safety of Visugromab plus Nivolumab with or without Docetaxel versus Docetaxel Monotherapy in Second-Line Treatment of Participants with Metastatic Non-Squamous Non-Small Cell Lung Cancer (GDFATHER-NSCLC-02)

Investigador Principal